Seventh Sense Biosystems has designed and developed TAP™, the world’s first push-button blood collection device. It makes the process simple, convenient, and virtually painless. $50 billion is spent annually on diagnostics and consumers are demanding more from the healthcare system. The company aims to create a new standard for blood collection that increases patient compliance with testing orders, leading to faster diagnoses and better outcomes. Future versions of TAP will enable patients to collect their own blood anywhere.
Mr. Weisman is an accomplished entrepreneur in the life sciences industry. Prior to joining Seventh Sense, he was the founder, chairman, and CEO of EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market. He also co-founded ESP Pharma, where he served as a director as well as the company’s president and chief operating officer until its sale to PDL Biopharma in 2005. Mr. Weisman began his career in sales and marketing at Merck & Co., later moving to Parke-Davis where he launched that company’s diabetes franchise in 1997. He graduated with a BA in chemistry from Rutgers University.
Mr. Richards joined Seventh Sense Biosystems in 2013, bringing a diverse set of international experience and expertise in general management, operations, commercial management, and strategy in the medical device field. Prior to Seventh Sense, Mr. Richards was president of Facet Technologies, a supplier to major diagnostic companies. Previous experience includes executive-level positions at Covidien, where he was president of US patient care and safety, and president of VNUS, a $440 million acquisition. He was also the chief marketing officer at B. Braun Medical, and held a number of commercial and strategic leadership positions with Becton Dickinson & Company in the US and Asia.
Mr. Richards received his BA from Lake Forest College and has participated in executive management and organizational development programs at Stanford Business School, the European School of Management and Technology, and American University.
Mr. Blitz brings a proven history of building medical device companies from an early stage. Prior to Seventh Sense, he was the first employee at AgaMatrix, a blood glucose monitoring company that made the world’s first medical device connecting directly to the iPhone. He helped grow the company from a startup to one with over 15 FDA-cleared products and 750 employees, forging partnerships with Apple, Sanofi, CVS, and Target. Stuart holds a B.S. in Biomedical Engineering from The Johns Hopkins University and an M.S. in Investment Management from Boston University.
Mr. Kofol is an experienced financial executive in the medical device and pharmaceutical industries. Mr. Kofol served as Vice President Treasurer and Investor Relations at Boston Scientific Corporation. Prior financial experience includes audit, domestic and international controllership and treasury positions at Wyeth Pharmaceuticals. Mr. Kofol received his BA degree from Presbyterian College and MBA from Wharton School. He also holds CPA certification.
Mr. Brightbill is an accomplished medical product development and commercialization engineer with more than 25 years of experience developing and marketing a wide variety of disposable medical and catheter-based vascular devices. He came to Seventh Sense from Vention Medical where he was the Program Manager. Prior to that, he was director of catheter research and development at Infraredx, Inc. where he designed, prototyped, tested, and commercialized near-infrared spectroscopy catheters to detect vulnerable plaque in coronary arteries.
Mr. Brightbill also worked for Medtronic AVE as an engineering manager and global marketing product manager, playing a key role in product acquisition and technology transfers. He has a BS in mechanical engineering from Bucknell University and an MBA from Northeastern University.
BOARD OF DIRECTORS
Alan Crane joined Polaris Partners in 2002 and serves as both a Partner and Entrepreneur focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra,Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics (acquired by Eagle Pharmaceuticals). In addition, he currently serves on the board of Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).
From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.
Prior to Polaris, Alan was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade® which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.
Alan received the Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: Selection Committee for the Harvard Life Lab,expert-in-residence at the Harvard School of Engineering, Board Member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and President of the Board of Gann Academy.
Alan earned a BA in Biology, summa cum laude, from Harvard College, an MA in Cellular and Developmental Biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.
Alan enjoys spending his free time traveling with his wife and three sons and working with non-profits in education and healthcare.